3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patient: Male, 76-year-old

          Final Diagnosis: Left atrial appendage thrombus despite optimal anticoagulation

          Symptoms: Palpitations

          Medication: —

          Clinical Procedure: Cryoballoon-based ablation • percutaneous left atrial appendage closure • transesophageal echocardiogram

          Specialty: Cardiology

          Objective:

          Unusual clinical course

          Background:

          Despite use of optimal oral anticoagulation regimens, left atrial appendage (LAA) thrombus may develop and persist in patients with atrial fibrillation (AF). The therapeutic options in this population are limited. Percutaneous LAA closure (LAAC) is performed to reduce thrombus formation and the risk of thromboembolism. However, this approach is prohibited in patients with LAA thrombus. We report the case of a 76-year-old man with AF and persistent LAA thrombus who underwent percutaneous LAAC with the LAmbre device protected by the SENTINEL Cerebral Protection System (CPS).

          Case Report:

          A 76-year-old man with history of persistent AF treated with pulmonary veins and LAA isolation developed LAA thrombus resistant to different anticoagulation therapies, including apixaban and Phenprocoumon, with a target international normalized ratio (INR) of 3–3,5. Repeated follow-up transesophageal echocardiography showed a persistent LAA thrombus despite optimal INR values. Thus, we performed a percutaneous LAAC using a double-umbrella-designed appendage occluder and a CPS to minimize the risk of intraprocedural cerebral embolization. The procedure was guided by transesophageal echocardiography and fluoroscopy. No signs of systemic thromboembolism were noted, and the CPS filters showed no evidence of thrombotic material.

          Conclusions:

          This report shows that the use of a CPS during percutaneous LAAC may reduce the risk of procedural cerebral embolization and could be used as an alternative therapy for patients with contraindication or lack of effectiveness of oral anticoagulation.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

          Circulation, 139(10)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            OUP accepted manuscript

            (2020)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation.

              Left atrial appendage obliteration was historically ineffective for the prevention of postoperative stroke in patients with rheumatic atrial fibrillation who underwent operative mitral valvotomy. It is, however, a routine part of modern "curative" operations for nonrheumatic atrial fibrillation, such as the maze and corridor procedures. To assess the potential of left atrial appendage obliteration to prevent stroke in nonrheumatic atrial fibrillation patients, we reviewed previous reports that identified the etiology of atrial fibrillation and evaluated the presence and location of left atrial thrombus by transesophageal echocardiography, autopsy, or operation. Twenty-three separate studies were reviewed, and 446 of 3,504 (13%) rheumatic atrial fibrillation patients, and 222 of 1,288 (17%) nonrheumatic atrial fibrillation patients had a documented left atrial thrombus. Anticoagulation status was variable and not controlled for. Thrombi were localized to, or were present in the left atrial appendage and extended into the left atrial cavity in 254 of 446 (57%) of patients with rheumatic atrial fibrillation. In contrast, 201 of 222 (91%) of nonrheumatic atrial fibrillation-related left atrial thrombi were isolated to, or originated in the left atrial appendage (p < 0.0001). These data suggest that left atrial appendage obliteration is a strategy of potential value for stroke prophylaxis in nonrheumatic atrial fibrillation.
                Bookmark

                Author and article information

                Journal
                Am J Case Rep
                Am J Case Rep
                amjcaserep
                The American Journal of Case Reports
                International Scientific Literature, Inc.
                1941-5923
                2022
                14 September 2022
                : 23
                : e937063-1-e937063-6
                Affiliations
                [1 ]Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany
                [2 ]Faculty of Medicine, ”Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
                [3 ]German Center for Cardiovascular Research (DZHK), Partner Site Lübeck, Lübeck, Germany
                Author notes
                Corresponding Author: Roland Richard Tilz, e-mail: tilz6@ 123456hotmail.com

                Authors’ Contribution:

                [A]

                Study Design

                [B]

                Data Collection

                [C]

                Statistical Analysis

                [D]

                Data Interpretation

                [E]

                Manuscript Preparation

                [F]

                Literature Search

                [G]

                Funds Collection

                Financial support: None declared

                Conflict of interest: CHH received travel grants and research grants from Boston Scientific, Biosense Webster, and Cardiofocus, and Speaker’s Honoraria from Boston Scientific, Biosense Webster, and Cardiofocus. RRT is a consultant of Boston Scientific, Biotronik and Biosense Webster and received Speaker’s Honoraria from Biosense Webster, Medtronic, Boston Scientific, and Abbot Medical. All other authors have no relevant disclosures

                Article
                937063
                10.12659/AJCR.937063
                9483240
                36101478
                a2beca4e-b44b-4ab5-972d-ba52e889cd7d
                © Am J Case Rep, 2022

                This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International ( CC BY-NC-ND 4.0)

                History
                : 26 April 2022
                : 29 June 2022
                : 15 August 2022
                Categories
                Articles

                atrial appendage,atrial fibrillation,intracranial embolism and thrombosis,thrombosis

                Comments

                Comment on this article